Armo scooped up by Lilly for $1.5bn
Eli Lilly & Co. will pay $50 per share (a 79% premium) or approximately $1.5bn to acquire immuno-oncology firm Armo BioSciences Inc. The deal provides a swift exit for Armo shareholders, as the company just went public through a $17 per share/$137mm initial public offering in January of this year.
- Large Molecule
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.